Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717781 | 0.88 | MEN1 (0.50) | MEN1KMT2ANLRP3ALDH1A1PTGS2 | |
| SCHEMBL718967 | 0.84 | MEN1 (0.53) | MEN1KMT2ANLRP3ADORA3ALDH1A1 | |
| SCHEMBL716051 | 0.82 | POLB (0.44) | MEN1KMT2ANLRP3ALDH1A1PTGS2 | |
| SCHEMBL718292 | 0.81 | PTGS2 (0.45) | MEN1KMT2ANLRP3ALDH1A1CNR1 | |
| SCHEMBL21271864 | 0.81 | PTGS2 (0.45) | MEN1KMT2ANLRP3ALDH1A1PTGS2 | |
| SCHEMBL28716311 | 0.81 | PTGS2 (0.65) | MEN1KMT2ANLRP3ALDH1A1CNR1 | |
| SCHEMBL719988 | 0.81 | MEN1 (0.56) | MEN1KMT2ANLRP3ADORA3ALDH1A1 | |
| SCHEMBL718659 | 0.81 | MEN1 (0.56) | MEN1KMT2ANLRP3ADORA3ALDH1A1 | |
| SCHEMBL23392554 | 0.80 | KMT2A (0.79) | MEN1KMT2ANLRP3ALDH1A1CNR1 | |
| SCHEMBL719535 | 0.80 | PTGS2 (0.63) | MEN1KMT2ANLRP3ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138321-B2 | Half-curcuminoids as amyloid-β PET imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2024-11-12 | — | — | US | disclosed |
| US-12102695-B2 | Half-curcuminoids as amyloid-beta pet imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-01 | — | — | US | disclosed |
| US-20220001035-A1 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2022-01-06 | — | — | US | disclosed |
| US-20220001036-A1 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2022-01-06 | — | — | US | disclosed |
| US-11135318-B2 | Half-curcuminoids as amyloid-beta PET imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-20190255198-A1 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2019-08-22 | — | — | US | disclosed |
| WO-2018005732-A1 | HALF-CURCUMINOIDS AS AMYLOID-BETA PET IMAGING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2373163-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885NLRP3 1630/4885 |
| US-20220001036-A1 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | APP, PSEN1, BACE1 | MEN1 246/4885KMT2A 3743/4885NLRP3 1455/4885 |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | MEN1 833/4885KMT2A 1696/4885NLRP3 2183/4885 |
| US-12102695-B2 | Half-curcuminoids as amyloid-beta pet imaging agents | APP, PSEN1, BACE1 | MEN1 246/4885KMT2A 3743/4885NLRP3 1455/4885 |
| US-20220001035-A1 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | APP, PSEN1, BACE1 | MEN1 246/4885KMT2A 3743/4885NLRP3 1455/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885NLRP3 1630/4885 |
| US-20190255198-A1 | Half-Curcuminoids as Amyloid-Beta PET Imaging Agents | APP, PSEN1, BACE1 | MEN1 246/4885KMT2A 3743/4885NLRP3 1455/4885 |
| US-12138321-B2 | Half-curcuminoids as amyloid-β PET imaging agents | APP, PSEN1, BACE1 | MEN1 257/4885KMT2A 3785/4885NLRP3 1405/4885 |
| US-11135318-B2 | Half-curcuminoids as amyloid-beta PET imaging agents | APP, PSEN1, BACE1 | MEN1 246/4885KMT2A 3743/4885NLRP3 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.